Peptide · Fact sheet
Retatrutide
Also known as LY3437943
Retatrutide activates GIP, GLP-1, and glucagon receptors and is being studied in Phase 3 programs. It is not an FDA-approved medicine.
What is Retatrutide?
Retatrutide is a manufactured peptide designed to activate three metabolic signaling receptors.
It remains a research drug. Registered trials are testing both benefits and risks in defined populations.
Benefits & claims
Early human studies reported substantial average weight changes, which generated strong public interest.
Phase 3 trials are intended to test whether those results hold up in larger, more diverse groups and to characterize safety more completely.
What the evidence supports
- Earlier trials observed changes in body weight and metabolic measures.
- Company-reported Phase 3 top-line results describe substantial weight changes in defined trial populations, but those reports should not be treated as FDA approval or complete published evidence.
- Ongoing Phase 3 and outcomes trials are designed to provide more reliable estimates of benefits and harms over time.
Research areas
- Obesity and overweight
- Type 2 diabetes
- Cardiovascular and kidney outcomes
- Obstructive sleep apnea
- Knee osteoarthritis in people with obesity or overweight
- Body-weight reduction and maintenance
- Metabolic and cardiovascular outcomes
- Obesity-related conditions
Dosage & frequency
Human study contextRetatrutide is an investigational triple agonist. Trial doses are not an approved weight-management schedule.
Phase 2 obesity trial
Adults meeting the study obesity or overweight criteria
- Amount
- Target groups 1, 4, 8 or 12 mg; higher-dose groups had different study-specific starting amounts
- Frequency
- Once weekly for 48 weeks
- Route studied or labeled
- Subcutaneous
Investigational dose-finding trial; target amounts are not a self-directed starting schedule.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Its GLP-1, GIP and glucagon activity is distinct from tirzepatide or semaglutide.
Interactions & precautions
- Triple-agonist trial regimens do not establish safety when combined with other GLP-1, GIP, or glucagon-directed medicines.
What is still unresolved
- Approved indication, commercial formulation, final titration, and long-term outcomes remain unresolved.
Side effects & risks
- Earlier trials reported gastrointestinal adverse effects, among other events.
- A research program may identify uncommon or longer-term risks only after larger and longer studies.
- Products marketed online as retatrutide are not an FDA-approved version of the investigational drug.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceA published Phase 2 obesity trial and company-reported Phase 3 top-line results provide human evidence, but peer-reviewed Phase 3 publications, full regulatory review, and longer outcomes data remain pending.
Studies
Registered Phase 3 obesity master trial with knee-osteoarthritis and obstructive-sleep-apnea substudies.
Registered Phase 3 comparison of retatrutide and tirzepatide in adults with obesity.
Registered cardiovascular and kidney outcomes trial.
Peer-reviewed Phase 2 dose-finding obesity trial that preceded the Phase 3 program.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| Retatrutide Phase 2 Adults with obesity or overweight plus a weight-related condition 338 participants (actual) Randomized placebo-controlled trial; human | Retatrutide versus Placebo 48 weeks; primary endpoint at 24 weeks Primary: Percentage body-weight change at week 24 Weight change at week 48 was secondary, not the primary endpoint. Phase: Phase 2 | Greater weight reductions than placebo were reported. Cannot tell us: A Phase 2 result is neither approval nor a direct comparison with semaglutide or tirzepatide. Safety, uncertainty, and source detailsGastrointestinal events and increases in heart rate were reported. Limited to the studied population, formulation and follow-up. Funding/conflicts: Funded by Eli Lilly; individual disclosures not fully extracted. Source checked: 2026-09-18. Independent clinical review: not completed. |
| TRIUMPH-1 Adults with obesity or overweight; defined substudies 2,335 participants (actual) Randomized placebo-controlled trial; human | Retatrutide versus Placebo Primary weight endpoint: 80 weeks Primary: Body-weight change; subgroup apnea and knee-pain outcomes Phase: Phase 3 | Registry marks the study completed; no results are posted in this registry snapshot. Cannot tell us: No posted registry results does not mean no results exist elsewhere. Publication search is not complete. Safety, uncertainty, and source detailsSee primary paper; absence of a signal in this study does not establish general safety. Limited to the studied population, formulation and follow-up. Funding/conflicts: Sponsor: Eli Lilly and Company. Source checked: 2026-09-18. Independent clinical review: not completed. |
| TRIUMPH-5 Adults with obesity 800 participants (estimated) Randomized placebo-controlled trial; human | Retatrutide versus Tirzepatide Primary weight endpoint: 80 weeks Primary: Percentage body-weight change Phase: Phase 3 | Active, not recruiting; no registry results posted at the source check. Cannot tell us: A registered head-to-head design is not a completed head-to-head result. Enrollment is estimated. Safety, uncertainty, and source detailsSee primary paper; absence of a signal in this study does not establish general safety. Limited to the studied population, formulation and follow-up. Funding/conflicts: Sponsor: Eli Lilly and Company. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
How do the Phase 2 publication and Phase 3 registry records differ?
Published Phase 2 weight outcomes and separate Phase 3 records can be inspected individually.
Limit: Registration, completion, company announcements and FDA approval are different events.
Check the sources: Retatrutide Phase 2 obesity trial (checked 2026-09-18) · TRIUMPH-1 registry record (checked 2026-09-18) · TRIUMPH-5 registry record (checked 2026-09-18)
Compare research questions · Submit a source-based correction
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Appetite: reported experiences
Early weight loss with disabling fatigue
An author described weight loss over two weeks, but fatigue and brain fog that interfered with exercise. They also reported continued hunger after previously using semaglutide and tirzepatide.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 2 mg starting amount, as reported
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Two weeks at the time of the post
Other exposures described: Prior semaglutide and tirzepatide use
This is an unverified product experience outside a confirmed trial. Prior treatment, diet and product identity limit attribution.
Read the original accountFatigue and skin tingling without a clear appetite change
A person using a product labeled retatrutide reported intense afternoon fatigue and skin tingling, with little perceived change in appetite. They also reported ongoing semaglutide exposure.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 4.5 mg when symptoms intensified, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About five weeks at the time of the post
Other exposures described: Concurrent semaglutide
This is not a verified clinical-trial participant. Combined exposure and unknown product identity prevent assignment of symptoms to retatrutide; it cannot estimate trial safety or efficacy.
Read the reported experienceLess hunger and weight loss, with a slight headache
Another poster described reduced appetite and a change from 109 kg to 104 kg by the fifth week, after already losing weight on a lower-calorie diet before starting.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 4 mg per week in total at the time of the post; previously 2 mg per week in total
- Frequency
- Divided into two uses per week
- Route
- Not specified clearly
- Duration
- Fifth week at the time of the post
The account and same-author clarification describe personal exposure, not a studied regimen. Ongoing dietary changes, unverified product identity and self-reported measurements limit attribution.
Read the original accountWeight: reported experiences
Early weight loss with disabling fatigue
An author described weight loss over two weeks, but fatigue and brain fog that interfered with exercise. They also reported continued hunger after previously using semaglutide and tirzepatide.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 2 mg starting amount, as reported
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Two weeks at the time of the post
Other exposures described: Prior semaglutide and tirzepatide use
This is an unverified product experience outside a confirmed trial. Prior treatment, diet and product identity limit attribution.
Read the original accountLess hunger and weight loss, with a slight headache
Another poster described reduced appetite and a change from 109 kg to 104 kg by the fifth week, after already losing weight on a lower-calorie diet before starting.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 4 mg per week in total at the time of the post; previously 2 mg per week in total
- Frequency
- Divided into two uses per week
- Route
- Not specified clearly
- Duration
- Fifth week at the time of the post
The account and same-author clarification describe personal exposure, not a studied regimen. Ongoing dietary changes, unverified product identity and self-reported measurements limit attribution.
Read the original accountEnergy: reported experiences
Early weight loss with disabling fatigue
An author described weight loss over two weeks, but fatigue and brain fog that interfered with exercise. They also reported continued hunger after previously using semaglutide and tirzepatide.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 2 mg starting amount, as reported
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Two weeks at the time of the post
Other exposures described: Prior semaglutide and tirzepatide use
This is an unverified product experience outside a confirmed trial. Prior treatment, diet and product identity limit attribution.
Read the original accountMore energy than during prior tirzepatide use
A commenter described more energy and no troublesome effects during their retatrutide experience, contrasting it with their earlier tirzepatide experience.
Amount, frequency, route and duration could not be confirmed for this account.
This selected self-report does not establish comparative tolerability, fat burning or confirmed exposure to trial-grade retatrutide.
Read the original accountFatigue and skin tingling without a clear appetite change
A person using a product labeled retatrutide reported intense afternoon fatigue and skin tingling, with little perceived change in appetite. They also reported ongoing semaglutide exposure.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 4.5 mg when symptoms intensified, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About five weeks at the time of the post
Other exposures described: Concurrent semaglutide
This is not a verified clinical-trial participant. Combined exposure and unknown product identity prevent assignment of symptoms to retatrutide; it cannot estimate trial safety or efficacy.
Read the reported experienceFocus: reported experiences
Early weight loss with disabling fatigue
An author described weight loss over two weeks, but fatigue and brain fog that interfered with exercise. They also reported continued hunger after previously using semaglutide and tirzepatide.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 2 mg starting amount, as reported
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- Two weeks at the time of the post
Other exposures described: Prior semaglutide and tirzepatide use
This is an unverified product experience outside a confirmed trial. Prior treatment, diet and product identity limit attribution.
Read the original accountSkin: reported experiences
Fatigue and skin tingling without a clear appetite change
A person using a product labeled retatrutide reported intense afternoon fatigue and skin tingling, with little perceived change in appetite. They also reported ongoing semaglutide exposure.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 4.5 mg when symptoms intensified, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About five weeks at the time of the post
Other exposures described: Concurrent semaglutide
This is not a verified clinical-trial participant. Combined exposure and unknown product identity prevent assignment of symptoms to retatrutide; it cannot estimate trial safety or efficacy.
Read the reported experienceHeadache: reported experiences
Less hunger and weight loss, with a slight headache
Another poster described reduced appetite and a change from 109 kg to 104 kg by the fifth week, after already losing weight on a lower-calorie diet before starting.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 4 mg per week in total at the time of the post; previously 2 mg per week in total
- Frequency
- Divided into two uses per week
- Route
- Not specified clearly
- Duration
- Fifth week at the time of the post
The account and same-author clarification describe personal exposure, not a studied regimen. Ongoing dietary changes, unverified product identity and self-reported measurements limit attribution.
Read the original accountSensory changes: reported experiences
Fatigue and skin tingling without a clear appetite change
A person using a product labeled retatrutide reported intense afternoon fatigue and skin tingling, with little perceived change in appetite. They also reported ongoing semaglutide exposure.
Reported use in this account
- Product
- Product labeled retatrutide
- Amount
- 4.5 mg when symptoms intensified, as reported
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About five weeks at the time of the post
Other exposures described: Concurrent semaglutide
This is not a verified clinical-trial participant. Combined exposure and unknown product identity prevent assignment of symptoms to retatrutide; it cannot estimate trial safety or efficacy.
Read the reported experienceApproval status
Retatrutide is not FDA approved. Some Phase 3 studies have reported company-provided top-line results, while other Phase 3, head-to-head, and outcomes studies remain ongoing or active in registries.
Late-stage clinical development
Retatrutide has Phase 3 trial records and company-reported top-line results, while other Phase 3 and outcomes studies remain in the registry. It is not FDA approved.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- How company-reported Phase 3 top-line findings will look after full peer-reviewed publication and regulatory review
- The complete adverse-effect profile across larger populations
- Which indications, populations, or product presentations might eventually be reviewed by regulators
- Long-term cardiovascular and kidney outcomes
Summary
Retatrutide remains investigational. Phase 3 findings and regulatory review will define its supported uses.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- clinical trialsClinicalTrials.gov: TRIUMPH-1 Phase 3 study
Registered Phase 3 obesity master trial with knee-osteoarthritis and obstructive-sleep-apnea substudies.
- company releaseLilly: TRIUMPH-1 top-line results
Company-provided Phase 3 top-line obesity results; not a peer-reviewed publication or FDA approval.
- clinical trialsClinicalTrials.gov: TRIUMPH-5 Phase 3 study
Registered Phase 3 comparison of retatrutide and tirzepatide in adults with obesity.
- clinical trialsClinicalTrials.gov: TRIUMPH-Outcomes
Registered cardiovascular and kidney outcomes trial.
- pubmedNEJM Phase 2 obesity trial indexed in PubMed
Peer-reviewed Phase 2 dose-finding obesity trial that preceded the Phase 3 program.